

NOV 28 2000

PHARMACY
MADISON, WI 53706

**Problems of Drug
Dependence, 1994:
Proceedings of the 56th Annual
Scientific Meeting, The College on Problems
of Drug Dependence, Inc.**

Volume II: Abstracts

Editor:

Louis S. Harris, Ph.D.

**NIDA Research Monograph 153
1995**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
National Institutes of Health**

**National Institute on Drug Abuse
5600 Fishers Lane
Rockville, MD 20857**

ACKNOWLEDGMENT

The College on Problems of Drug Dependence, Inc., an independent, nonprofit organization, conducts drug testing and evaluations for academic institutions, government, and industry. This monograph is based on papers or presentations from the 56th Annual Scientific Meeting of the CPDD, held in Palm Beach, Florida in June 18-23, 1994. In the interest of rapid dissemination, it is published by the National Institute on Drug Abuse in its Research Monograph series as reviewed and submitted by the CPDD. Dr. Louis S. Harris, Department of Pharmacology and Toxicology, Virginia Commonwealth University was the editor of this monograph.

COPYRIGHT STATUS

The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder's permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated.

Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the Department of Health and Human Services.

The U.S. Government does not endorse or favor any specific commercial product or company. Trade, proprietary, or company names appearing in this publication are used only because they are considered essential in the context of the studies reported herein.

NIH Publication No. 95-3883
Printed 1995

NIDA Research Monographs are indexed in the Index Medicus. They are selectively included in the coverage of *American Statistics Index*, *BioSciences Information Service*, *Chemical Abstracts*, *Current Contents*, *Psychological Abstracts*, and *Psychopharmacology Abstracts*.

TOLERABILITY STUDY OF A DEPOT FORM OF NALTREXONE SUBSTANCE ABUSERS

T. N. Alim, B. Tai, C. N. Chiang, T. Green, R. B. Rosse, T. Lindquist, and S. I. Deutsch

INTRODUCTION: Oral naltrexone has been associated with a high early dropout rate. A injectable depot form of naltrexone could improve compliance in otherwise poorly motivated opiate addicts. A previous sustained release preparation of naltrexone using 1.5 mm diameter spheres showed opiate receptor blockade but some subjects developed tissue inflammation. In the current study, we evaluate the safety and tolerability of a depot form of naltrexone with smaller microspheres (105-150 μ m). **SUBJECTS:** Eight cocaine dependent males (34.1 years of age, range = 23-45) with no evidence of opiate dependence and in good physical health were subjects in the study. One subject on the high dose was excluded due to adverse effect of the morphine challenge. **DESIGN:** The study was a double-blind, placebo-controlled two dose inpatient/outpatient study. Subjects were evaluated for 64 days. **LOW DOSE PHASE** (n=4, 3 drug, 1 placebo): Subjects received 1.2 cc (103 mg) of naltrexone preparation or placebo subcutaneously in triceps of each arm (one arm received placebo). When subjects did not experience severe side effects to this low dose after 64 days, the high dose phase was conducted. **HIGH DOSE PHASE** (n=4, 3 drug, 1 placebo): Subjects received 2.4 cc (206 mg) of naltrexone preparation or placebo in a similar fashion to the low dose group. Plasma naltrexone levels were obtained during both phases. **RESULTS:** Subjects generally reported mild injection site pain; erythema was observed in most subjects, but was not severe and subsided over the course of the study. Induration without pain or discomfort was the most persistent side effect. Blood chemistries and CBC did not change significantly over the course of the study. **Morphine challenge:** Subjects in the high dose group were challenged with 10 mg IV morphine on days 8, 15, 22, and 29 of the inpatient stay. Opiate receptor blockade was observed although physiologic and subjective responses were variable. **CONCLUSIONS:** The depot formulation of naltrexone used in this study appeared well-tolerated and resulted in plasma levels of 1 ng/ml or greater for more than three weeks. Higher doses of opiate agonists may better assess efficacy of this depot formulation of naltrexone. Future studies to assess the acceptability, tolerance, and efficacy of depot naltrexone in outpatient detoxified opiate addicts appear indicated.

ACKNOWLEDGEMENT:

This research was supported by Inter-Agency Agreement RA-ND-90-10 between the National Institute on Drug Abuse and the Department of Veteran's Affairs.

AFFILIATION:

National Institute on Drug Abuse and the Department of Veteran's Affairs, Rockville, MD